In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...
Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...
This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a ...
Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...
The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...
Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...
PE: What is the reaction to DTC pharma advertising? Donaldson: Consumers will slowly but surely have increased distrust in ...
Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step ...
Novo Nordisk partners with Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, while GSK ...
Otsuka America Pharmaceutical’s president and CEO Tarek Rabah spoke with Pharmaceutical Executive about the company’s mission ...
Astellas Pharma Inc. and Vir Biotechnology, Inc. have entered into a global strategic collaboration to advance VIR-5500, an ...
Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results